Clinical trial
ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an…
NCT00461266 · Hoffmann-La Roche, Industry · Withdrawn
Key facts
| NCT number | NCT00461266 |
|---|---|
| Title | ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression. |
| Official title | A Randomized, Open Label Study to Determine the Immunological Benefits of Adding Fuzeon to an Antiretroviral Regimen in HIV-infected Fuzeon-naïve Patients With Sustained HIV Viral Suppression |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | enfuvirtide [Fuzeon], Antiretroviral therapy |
| Enrollment | 0 |
| Start date | Apr 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Apr 17, 2007 |
| Last update posted | Aug 24, 2016 |
| Countries | Australia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: